In This Article:
-
Revenue: $11.8 million, up 59% from the prior-year period.
-
Handheld Product and Service Revenue: $11 million, up 86% from the prior-year period.
-
Recurring Revenue: $4.4 million, representing 37% of total revenues, up 54% from the prior-year period.
-
Gross Margin: 47%, compared to 52% in the prior-year period.
-
Adjusted Gross Margin: 54%, an increase of approximately 75 basis points from the prior-year period.
-
Net Loss from Continuing Operations: $9.8 million, compared to $5.9 million in the prior-year period.
-
Adjusted EBITDA Loss: $4.6 million, an improvement from a loss of $5.3 million in the prior-year period.
-
Cash Position: $124.3 million in cash, cash equivalents, and marketable securities, with no debt outstanding.
-
Device Shipments: 157 devices shipped in Q1 2025, compared to 53 devices in Q1 2024.
-
Full Year Revenue Guidance: Expected to be in the range of $53 million to $55 million, representing growth of 11% to 15% over full year 2024.
Release Date: May 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Revenue from continuing operations increased by 59% year-over-year, reaching $11.8 million.
-
Recurring revenue grew by 54% from the previous year, representing 37% of total revenues.
-
The company completed the divestiture of its biopharma desktop portfolio, strengthening its cash position.
-
908 Devices Inc (NASDAQ:MASS) received significant orders, including a $2 million order from the Texas Department of Public Safety.
-
The company is targeting positive adjusted EBITDA by Q4 2025 and full-year cash flow positivity in 2026.
Negative Points
-
Gross margin decreased to 47% from 52% in the prior-year period, primarily due to intangible amortization from the RedWave acquisition.
-
Net loss from continuing operations increased to $9.8 million compared to $5.9 million in the prior-year period.
-
Total operating expenses rose to $16.6 million from $11.5 million in the prior-year period.
-
The company is not assuming any meaningful revenue contribution from the US Department of Defense AVCAD program in 2025.
-
There is potential risk of delays in the decision to move forward with full-rate production for the AVCAD program.
Q & A Highlights
Q: Can you provide insights on the benefits from the RedWave acquisition and your ability to meet global demand? A: Kevin Knopp, CEO, highlighted that the integration with RedWave has been successful, expanding their product portfolio from one to four, which diversifies revenue streams. The sales team is effectively cross-selling, and they have a robust sales and marketing team in place to drive growth. The demand is accelerating due to macro pressures, and they are well-positioned to meet it.